Quantcast

Latest NeoGenomics Inc. Stories

2014-08-22 08:24:45

FT. MYERS, Fla., Aug. 22, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading provider of cancer-focused genetic testing services, today announced that it has closed on the public offering of an additional 1.05 million shares of common stock at an offering price of $4.60 per share as a result of the exercise in full of the underwriters' over-allotment option. The total gross proceeds of the offering, including the exercise in full of the over-allotment...

2014-08-15 08:24:55

Seven Million Share Offering at $4.60 per Share FT. MYERS, Fla., Aug. 15, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading provider of cancer-focused genetic testing services, today announced that it has priced an underwritten public offering of 7.0 million shares of common stock at a price to the public of $4.60 per share. The transaction is expected to close on August 20, 2014 and will result in gross proceeds to NeoGenomics of $32.2 million. The...

2014-08-14 16:26:50

FORT MYERS, Fla., Aug. 14, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by NeoGenomics. William Blair & Company, L.L.C. is the sole book-running manager and Craig-Hallum Capital Group LLC is co-lead manager for the offering. Stephens Inc., Roth Capital Partners,...

2014-07-11 08:24:23

Company Provides Widest Variety of Actionable Next-Gen Cancer Profiles FT. MYERS, Fla., July 11, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today it has launched 23 new and innovative NeoTYPE(TM) Cancer Profiles based on next-generation sequencing (NGS). These new advanced cancer-profiling tools offer oncologists and pathologists a more targeted and comprehensive ability to tailor...

2014-07-08 16:25:49

Adds Specialized Anatomic Pathology Services FORT MYERS, Fla., July 8, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, today announced that it has acquired Path Labs, LLC d/b/a Path Logic. Path Logic is a leading provider of specialized anatomic pathology services to Hospitals and physicians in Northern California. Path Logic provides high-quality Anatomic Pathology services with significant expertise in the...

2014-06-23 08:28:49

Company Experiencing Strong Test Volume Growth FT. MYERS, Fla., June 23, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, announced today that it was raising its previously issued revenue guidance for Quarter 2, 2014. The Company now expects revenue of approximately $20.0 - $20.5 million for the second quarter of 2014 compared with its previous estimate of $18.8 - $19.3 million. The Company also reaffirmed its...

2014-05-08 08:32:09

Alliance provides Aurora with a broad array of oncology specialty testing to complement its current anatomic pathology services in dermatology, gastroenterology, urology and women's health FT. MYERS, Fla., May 8, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has been selected by Aurora Diagnostics to be its primary partner for molecular testing at each of Aurora's 19...

2014-04-03 12:28:42

FT. MYERS, Fla., April 3, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its first quarter 2014 financial results on Wednesday April 23, 2014. The Company has scheduled a web-cast and conference call to discuss their Q1 2014 results on Wednesday April 23, 2014 at 11:00 AM EDT. Interested investors should dial (877) 407-0782 (domestic) and (201) 689-8567 (international) at least five minutes prior to the call and ask for Conference ID...

2014-03-18 08:31:43

Company is First to Offer Plasma-Based Next Generation Sequencing Tests FORT MYERS, Fla., March 18, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched the first two of a series of next generation cancer profiling tests. These tests are designed for profiling myelodysplastic syndrome (MDS) and solid tumor cancers. Additional cancer-type specific next...

2014-02-19 08:30:32

Company Set to Launch Next Generation Sequencing Services in March 2014 FT. MEYERS, Fla., Feb. 19, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year of 2013. Fourth Quarter 2013 Highlights: -- Revenue growth of 23% -- Test volume growth of 28% -- Gross Profit Margin of 50.0% versus 43.2% last year -- Adjusted EBITDA((1)) growth of 90% --...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related